Considering CSCs’ role in therapy resistance, we have evaluated the potential correlations between the clinicopathological parameters of LARC patients with a tumor fragmentation pattern following nCRT and TME and the immunoexpression of their biomarkers, aiming to refine the ypT3 stage through the identification of factors for risk stratification. Here, RAB11B is linked to neoplasm.